Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

• Published in: Journal of Crohn's and colitis Vol. 10; no. 1; pp. 26 - 30
• Main Authors: Bálint, Anita, Farkas, Klaudia, Palatka, Károly, Lakner, Lilla, Miheller, Pál, Rácz, István, Hegede, Gábor, Vincze, Áron, Horváth, Gábor, Szabó, Andrea, Nagy, Ferenc, Szepes, Zoltán, Gábor, Zoltán, Zsigmond, Ferenc, Zsóri, Ágnes, Juhász, Márk, Csontos, Ágnes, Szűcs, Mónika, Bor, Renáta, Milassin, Ágnes, Rutka, Mariann, Molnár, Tamás
• Format: Journal Article
• Language: English
• Published: UK Oxford University Press 01.01.2016
• Subjects: Adalimumab - administration & dosage; Adalimumab - adverse effects; Adolescent; Adult; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - adverse effects; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Cohort Studies; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - pathology; Colitis, Ulcerative - physiopathology; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hungary; Intestinal Mucosa - drug effects; Intestinal Mucosa - pathology; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Prospective Studies; Recurrence; Risk Assessment; Tertiary Care Centers; Treatment Outcome; Wound Healing - drug effects; Wound Healing - physiology; Young Adult; Hungary; continuous clinical response; adalimumab; Ulcerative colitis; mucosal healing
• ISSN: 1873-9946; 1876-4479
• DOI: 10.1093/ecco-jcc/jjv169

Background and Aim: Adalimumab [ADA] was approved for the treatment of ulcerative colitis [UC] refractory to conventional therapy in 2012 in Europe. Due to the observed discrepancies between clinical trials and practice, data on the outcome of ADA therapy are really needed from the real life. The aim of this study was to estimate the short- and long-term efficacy and safety of ADA in UC patients from each Hungarian biological centre. Patients and Methods: This prospective study consisted of UC patients treated with ADA in 10 Hungarian inflammatory bowel disease centres. The primary endpoints of the study were rates of continuous clinical response, remission, non-response and loss of response at Weeks 12, 30, and 52.The secondary endpoints included mucosal healing at Week 52 and the comparison of the efficacy of ADA between biological naive and infliximab [IFX]-treated groups. Colonoscopy was performed before starting the therapy and at Week 52. Results: In all, 73 active UC patients were enrolled in the study: 67.1% of the patients received previous IFX therapy; 75.3% of the patients showed short-term clinical response at Week 12. The probability of maintaining ADA was 48.6% at Week 52 with a continuous clinical response in 92% of these remaining patients. Mucosal healing was achieved in 48.1% of the patients at Week 52. Escalation of ADA was performed in 17.6%, and minor side effects developed in 4% of the patients; 5.4% of the patients underwent colectomy during the 1-year treatment period. Conclusion: UC is a progressive disease that may need early aggressive therapy to prevent structural and functional complications. The results of our study demonstrated the favourable efficacy of short- and long-term ADA treatment for patients with UC.